This NDC is on FDA's drug shortage list (posted Mar 1, 2017)
Reported reason: Demand increase for the drug
Product Information
SODIUM BICARB 8.4% SYRINGE is a generic product labeled by International Medication Systems, Limited, priced at $0.3288 per ML under NDC 76329335201. Its NADAC has been published 165 times since Apr 22, 2015.
FDA first approved this application on Sep 19, 2017. Its Orange Book therapeutic-equivalence code is AP.
Strength
84 mg/mL
Manufacturer
International Medication Systems, LimitedNDC
76329335201
Classification
Generic
Dosage Form
INJECTION
Route
INTRAVENOUS
Effective Date
12/18/2024
Active Ingredients
SODIUM BICARBONATEApproval Type
Generic (ANDA)
FDA Application
ANDA203449FDA Approved
9/19/2017
TE Code
AP
On Market Since
6/1/2000
Price Statistics
The NADAC for SODIUM BICARB 8.4% SYRINGE has been published 165 times since Apr 22, 2015, and over the history we have for it it has risen 177.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3288 per ML |
|---|---|
| All-time high | $0.3288 (Dec 10, 2025) |
| All-time low | $0.1186 (Apr 22, 2015) |
| 52-week high | $0.3288 |
| 52-week low | $0.3288 |
| Median price | $0.1489 |
| Average price | $0.2159 |
| Largest weekly change | +117.0% (Aug 21, 2024) |
| Weeks tracked | 165 |
| Tracking since | Apr 22, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
0.0%
3Y
+120.9%
5Y
+120.9%
All
+177.3%
Last surveyed Dec 10, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 53% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
International Medication Systems, Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sodium Bicarbonate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SODIUM BICARB 8.4% SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for SODIUM BICARB 8.4% SYRINGE, manufactured by International Medication Systems, Limited, is $0.3288 per ML (NDC 76329335201), effective Dec 10, 2025.
How has the price of SODIUM BICARB 8.4% SYRINGE changed over time?
Over the history we have for it, the NADAC for SODIUM BICARB 8.4% SYRINGE has risen 177.3%. It has been tracked across 165 weekly CMS publications since Apr 22, 2015.
What are the highest and lowest recorded NADAC prices for SODIUM BICARB 8.4% SYRINGE?
Since Apr 22, 2015, the NADAC for SODIUM BICARB 8.4% SYRINGE has ranged from a low of $0.1186 (Apr 22, 2015) to a high of $0.3288 (Dec 10, 2025), with a median of $0.1489 per ML.
Are there cheaper alternatives to SODIUM BICARB 8.4% SYRINGE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SODIUM BICARBONATE 8.4% VIAL, is $0.1540 per ML — about 53% below SODIUM BICARB 8.4% SYRINGE.
Who manufactures SODIUM BICARB 8.4% SYRINGE?
SODIUM BICARB 8.4% SYRINGE (NDC 76329335201) is labeled by International Medication Systems, Limited, and CMS classifies it as a generic product.
Is SODIUM BICARB 8.4% SYRINGE in shortage?
Yes — NDC 76329335201 is currently listed in FDA's drug shortage database (posted Mar 1, 2017). Reported reason: Demand increase for the drug.